Literature DB >> 26013006

An IL-27/Lag3 axis enhances Foxp3+ regulatory T cell-suppressive function and therapeutic efficacy.

J-S Do1, A Visperas1,2, Y O Sanogo3, J J Bechtel1, N Dvorina1, S Kim1, E Jang1, S A Stohlman4, B Shen5, R L Fairchild1, W M Baldwin1, D A A Vignali2,6, B Min1.   

Abstract

Foxp3-expressing regulatory T cells (Tregs) are central regulators of immune homeostasis and tolerance. As it has been suggested that proper Treg function is compromised under inflammatory conditions, seeking for a pathway that enhances or stabilizes Treg function is a subject of considerable interest. We report that interleukin (IL)-27, an IL-12 family cytokine known to have both pro- and anti-inflammatory roles in T cells, plays a pivotal role in enhancing Treg function to control T cell-induced colitis, a model for inflammatory bowel disease (IBD) in humans. Unlike wild-type (WT) Tregs capable of inhibiting colitogenic T-cell expansion and inflammatory cytokine expression, IL-27R-deficient Tregs were unable to downregulate inflammatory T-cell responses. Tregs stimulated with IL-27 expressed substantially improved suppressive function in vitro and in vivo. IL-27 stimulation of Tregs induced expression of Lag3, a surface molecule implicated in negatively regulating immune responses. Lag3 expression in Tregs was critical to mediate Treg function in suppressing colitogenic responses. Human Tregs also displayed enhanced suppressive function and Lag3 expression following IL-27 stimulation. Collectively, these results highlight a novel function for the IL-27/Lag3 axis in modulating Treg regulation of inflammatory responses in the intestine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26013006      PMCID: PMC4662649          DOI: 10.1038/mi.2015.45

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  42 in total

1.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

2.  Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora.

Authors:  Yingzi Cong; Casey T Weaver; Audrey Lazenby; Charles O Elson
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

3.  Role of LAG-3 in regulatory T cells.

Authors:  Ching-Tai Huang; Creg J Workman; Dallas Flies; Xiaoyu Pan; Aimee L Marson; Gang Zhou; Edward L Hipkiss; Sowmya Ravi; Jeanne Kowalski; Hyam I Levitsky; Jonathan D Powell; Drew M Pardoll; Charles G Drake; Dario A A Vignali
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

4.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

5.  Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells.

Authors:  Christian Mottet; Holm H Uhlig; Fiona Powrie
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

6.  Development of Th1-type immune responses requires the type I cytokine receptor TCCR.

Authors:  Q Chen; N Ghilardi; H Wang; T Baker; M H Xie; A Gurney; I S Grewal; F J de Sauvage
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

7.  IL-27 inhibits the development of regulatory T cells via STAT3.

Authors:  Magdalena Huber; Vera Steinwald; Anna Guralnik; Anne Brüstle; Peter Kleemann; Christine Rosenplänter; Thomas Decker; Michael Lohoff
Journal:  Int Immunol       Date:  2007-12-21       Impact factor: 4.823

8.  CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4.

Authors:  Haiying Liu; Bin Hu; Damo Xu; Foo Y Liew
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

9.  Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.

Authors:  F Powrie; M W Leach; S Mauze; S Menon; L B Caddle; R L Coffman
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  47 in total

1.  γδ T Cells Coexpressing Gut Homing α4β7 and αE Integrins Define a Novel Subset Promoting Intestinal Inflammation.

Authors:  Jeong-Su Do; Sohee Kim; Karen Keslar; Eunjung Jang; Emina Huang; Robert L Fairchild; Theresa T Pizarro; Booki Min
Journal:  J Immunol       Date:  2016-12-07       Impact factor: 5.422

Review 2.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 3.  Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature.

Authors:  Caroline Andrews; Mairi H McLean; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

Review 4.  Regulation of the T Cell Response by CD39.

Authors:  Maisa C Takenaka; Simon Robson; Francisco J Quintana
Journal:  Trends Immunol       Date:  2016-05-25       Impact factor: 16.687

5.  Treg-specific IL-27Rα deletion uncovers a key role for IL-27 in Treg function to control autoimmunity.

Authors:  Jeongsu Do; Dongkyun Kim; Sohee Kim; Alice Valentin-Torres; Nina Dvorina; Eunjung Jang; Vivekananthan Nagarajavel; Tara M DeSilva; Xiaoxia Li; Angela H Ting; Dario A A Vignali; Stephen A Stohlman; William M Baldwin; Booki Min
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

6.  IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors.

Authors:  Jonathan H DeLong; Aisling O'Hara Hall; Matt Rausch; Devapregasan Moodley; Joseph Perry; Jeongho Park; Anthony T Phan; Daniel P Beiting; Ross M Kedl; Jonathan A Hill; Christopher A Hunter
Journal:  Immunohorizons       Date:  2019-01-15

Review 7.  Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Authors:  Anabelle Visperas; Dario A A Vignali
Journal:  J Immunol       Date:  2016-11-15       Impact factor: 5.422

8.  Cytokine- and TCR-Mediated Regulation of T Cell Expression of Ly6C and Sca-1.

Authors:  Jonathan H DeLong; Aisling O'Hara Hall; Christoph Konradt; Gaia M Coppock; Jeongho Park; Gretchen Harms Pritchard; Christopher A Hunter
Journal:  J Immunol       Date:  2018-01-22       Impact factor: 5.422

9.  Cutting Edge: IL-27 Attenuates Autoimmune Neuroinflammation via Regulatory T Cell/Lag3-Dependent but IL-10-Independent Mechanisms In Vivo.

Authors:  Dongkyun Kim; Hongnga T Le; Quang Tam Nguyen; Sohee Kim; Juyeun Lee; Booki Min
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

Review 10.  IL-27-induced modulation of autoimmunity and its therapeutic potential.

Authors:  Rakeshchandra R Meka; Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Autoimmun Rev       Date:  2015-08-05       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.